The study is being conducted to evaluate the safety, tolerability and pharmacokinetics of HRS-4029 following a single intravenous dose administration in healthy subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
55
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China
The incidence and severity of adverse events
Time frame: From ICF signing date to Day15
Maximum observed concentration of HRS-4029 (Cmax)
Time frame: 0 hour to 48 hour after administration
Area under the serum concentration time curve (AUC) of HRS-4029
Time frame: 0 hour to 48 hour after administration
Time to maximum observed concentration (Tmax) of HRS-4029
Time frame: 0 hour to 48 hour after administration
Half-life (T1/2) of HRS-4029
Time frame: 0 hour to 48 hour after administration
Clearance (CL) of HRS-4029
Time frame: 0 hour to 48 hour after administration
Volume of distribution (Vz) of HRS-4029
Time frame: 0 hour to 48 hour after administration
Number of subjects who developed HRS-4029 antidrug antibodies (ADA)
Time frame: Baseline to Day15
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.